BackTable / Urology / Podcast / Episode #169
Prostate Cancer: Navigating Focal Therapy Options
with Dr. Matthew Cooperberg and Dr. Arvin George
In this episode, Dr. Matthew Cooperberg (UC San Francisco) and Dr. Arvin George (Johns Hopkins) join host Dr. Aditya Bagrodia in a conversation about guidelines and treatment algorithms for focal therapy in prostate cancer treatment.
This podcast is supported by:
Be part of the conversation. Put your sponsored messaging on this episode. Learn how.
BackTable, LLC (Producer). (2024, May 28). Ep. 169 – Prostate Cancer: Navigating Focal Therapy Options [Audio podcast]. Retrieved from https://www.backtable.com
Stay Up To Date
Follow:
Subscribe:
Sign Up:
Podcast Contributors
Dr. Matthew Cooperberg
Dr. Matthew Cooperberg is a professor at UCSF in San Francisco, California.
Dr. Arvin George
Dr. Arvin George is an associate professor of urology at the University of Michigan in Ann Arbor.
Dr. Aditya Bagrodia
Dr. Aditya Bagrodia is an associate professor of urology and genitourinary oncology team leader at UC San Diego Health in California and adjunct professor of urology at UT Southwestern.
Synopsis
First, the doctors discuss focal therapy in prostate cancer treatment from various perspectives, including the challenges of treating certain lesions, the comparison of different focal therapy modalities like high-intensity focused ultrasound (HIFU) and brachytherapy, cryotherapy and the importance of patient-specific factors in treatment decisions. They emphasize the need for clinical trials and registries to validate focal therapy outcomes, the potential expansion of indications for focal therapy, and the critical role of advanced imaging and genomic classifiers in patient selection and treatment planning. The discussion also touches on the potential of focal therapy to evolve as a standard care option alongside advancements in understanding the biology of prostate cancer and improving imaging and treatment technologies.
Timestamps
00:00 - Introduction
05:24 - Focal Therapy Definitions, Techniques, and Patient Selection
11:45 - Ideal Patients for Focal Therapy
25:30 - The Role of Genomic Classifiers in Treatment Decisions
30:56 - Addressing High-Risk Patient Concerns
37:51 - Advancements and Considerations in Focal Therapy Modalities
56:13 - The Future of Focal Therapy
Resources
Siemens Healthineers Theranostics:
https://www.siemens-healthineers.com/en-us/clinical-specialities/theranostics
Decipher Prostate Genomic Classifier by Veracyte:
https://decipherbio.com/decipher-prostate/physicians/decipher-prostate-overview/
Transcript Preview
[Dr. Matt Cooperberg]:
There's this old saying that in surgical oncology, biology is king, and all the surgeons, and here you can throw in radiation oncologists and focal therapists and everybody else are the princess trying to overthrow the king, often to no avail. I think ultimately, it comes down to understanding the cancer more and more at the biological level. I think that the role for focal therapy is clearly going to grow as we can identify those tumors that are actually confined to the prostate, and we can visualize them with imaging, increasingly with functional imaging, as our focal modalities get more and more guided by real-time feedback from imaging.
Clearly, it makes sense. You look at the history, everyone always draws the analogy to breast cancer and lumpectomy, taking over from mastectomy. Obviously, there's a lot of different considerations in prostate compared to breast but nonetheless, the idea of treating the tumor rather than the prostate makes a lot of sense for a certain band of cancers. As we're able to identify that band, figure out the ones that need treatment and yet need less than total treatment and pelvic treatment, as we can identify those and target them, of course, the role here will continue to grow.
The only way we're going to identify those tumors is to take this seriously, to as we've said at the beginning, put patients that are undergoing focal therapy in a registry, on a trial, collect the data, be honest about our outcomes, and constantly be striving to improve those outcomes with research and improvements in our treatments.
Disclaimer: The Materials available on BackTable.com are for informational and educational purposes only and are not a substitute for the professional judgment of a healthcare professional in diagnosing and treating patients. The opinions expressed by participants of the BackTable Podcast belong solely to the participants, and do not necessarily reflect the views of BackTable.